Oragenics Inc., of Tampa, Fla., said it closed its underwritten public offering of 16.66 million shares, short-term warrants to purchase up to 8.33 million shares, and long-term warrants to purchase up to 8.33 million shares, at $0.75 per share and accompanying warrants. The company expects to receive gross proceeds of approximately $12.5 million from the offering.